Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROTHENA CORPORATION PLC

(PRTA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/16/2021 09/17/2021 09/20/2021 09/21/2021 09/22/2021 Date
74.79(c) 77.07(c) 74.81(c) 75.03(c) 76.06 Last
253 245 795 575 285 776 317 111 267 458 Volume
-0.04% +3.05% -2.93% +0.29% +1.37% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 214 M - -
Net income 2021 68,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 52,6x
Yield 2021 -
Sales 2022 36,7 M - -
Net income 2022 -102 M - -
Net Debt 2022 - - -
P/E ratio 2022 -35,7x
Yield 2022 -
Capitalization 3 426 M 3 426 M -
Capi. / Sales 2021 16,0x
Capi. / Sales 2022 93,4x
Nbr of Employees 66
Free-Float 99,7%
More Financials
Company
Prothena Corporation PLC is an Ireland-based late-stage clinical company. The Company provides solutions for protein dysregulation and a pipeline of investigational therapeutics to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. It operates pipeline of therapeutic candidates to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins... 
Sector
Biotechnology & Medical Research
Calendar
09/27 | 11:20amPresentation
More about the company
Ratings of Prothena Corporation plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about PROTHENA CORPORATION PLC
09/20PROTHENA : Fox Advisors Initiates Coverage on Prothena With Overweight Rating
MT
09/17PROTHENA : Cantor Fitzgerald Adjusts Price Target on Prothena to $103 From $70, Maintains ..
MT
09/14PROTHENA : Oppenheimer Adjusts Prothena PT to $90 From $82 on Increased Optimism for the C..
MT
09/10PROTHENA : Corporate Overview
PU
09/06PROTHENA : Announces inducement grant under nasdaq listing rule 5635(4)
AQ
09/03PROTHENA : Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
09/01PROTHENA : to Participate in Upcoming September Healthcare Conferences
AQ
08/31PROTHENA : Corporate Overview
PU
08/23PROTHENA : Corporate Overview
PU
08/09PROTHENA : Oppenheimer Adjusts Prothena PT to $82 From $76, Maintains Outperform Rating
MT
08/05PROTHENA : PUBLIC LTD CO MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
AQ
08/05PROTHENA : Q2 Earnings Snapshot
AQ
08/05PROTHENA : Earnings Flash (PRTA) PROTHENA CORPORATION Posts Q2 Revenue $60.1M, vs. Street ..
MT
08/05PROTHENA CORP PUBLIC LTD CO : Results of Operations and Financial Condition (form 8-K)
AQ
08/05Prothena Corporation plc Revises Earnings Guidance for the Year 2021
CI
More news
News in other languages on PROTHENA CORPORATION PLC
07/12NOVO NORDISK : acquisition d'un programme auprès de Prothena
2020Morning Briefing - Markt Schweiz
More news
Analyst Recommendations on PROTHENA CORPORATION PLC
More recommendations
Chart PROTHENA CORPORATION PLC
Duration : Period :
Prothena Corporation plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTHENA CORPORATION PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 76,06 $
Average target price 75,86 $
Spread / Average Target -0,27%
EPS Revisions
Managers and Directors
Gene G. Kinney President, Chief Executive Officer & Director
Tran B. Nguyen Chief Operating & Financial Officer
Lars G. Ekman Chairman
Wagner M. Zago Chief Scientific Officer
Hideki Garren Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTHENA CORPORATION PLC533.31%3 380
GILEAD SCIENCES, INC.23.12%89 936
BIONTECH SE318.73%82 443
WUXI APPTEC CO., LTD.36.63%69 407
REGENERON PHARMACEUTICALS33.91%67 262
VERTEX PHARMACEUTICALS-21.38%48 202